The latest medical research on Respiratory Medicine

The research magnet gathers the latest research from around the web, based on your specialty area. Below you will find a sample of some of the most recent articles from reputable medical journals about respiratory medicine gathered by our medical AI research bot.

The selection below is filtered by medical specialty. Registered users get access to the Plexa Intelligent Filtering System that personalises your dashboard to display only content that is relevant to you.

Want more personalised results?

Request Access

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.

Respirology

Antifibrotic therapy with nintedanib or pirfenidone slows disease progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF). However, patients with advanced IPF, as defined by forced vital capacity (FVC) < 50% and/or diffusion capacity for carbon monoxide (DLCO) < 30% of predicted, have not been included in randomized trials, and the outcomes of such patients who initiate treatment are not well understood. We determined lung function, disease progression and mortality outcomes following initiation of antifibrotic therapy in patients with advanced IPF at the time of treatment initiation compared to those with mild-moderate IPF.

We included 502 patients enrolled in IPF registries from four Nordic countries. Linear mixed models were used to assess change in FVC and DLCO over time. Cox proportional hazards models were used to assess transplant-free survival and progression- and transplant-free survival.

Of 502 patients, 66 (13%) had advanced IPF. Annual change in FVC was -125 ml (95% CI -163, -87) among patients with mild-moderate IPF, and +28 ml (95% CI -96, +152) among those with advanced IPF. Advanced IPF at treatment initiation was associated with poorer transplant-free survival (hazard ratio [HR] 2.39 [95% CI 1.66, 3.43]) and progression- and transplant-free survival (HR 1.60 [95% CI 1.15, 2.23]).

In a broadly representative IPF population, patients with advanced IPF at the initiation of antifibrotic therapy did not have greater lung function decline over time compared with those with mild-moderate IPF, but had substantially higher mortality. Prospective studies are needed to determine the effect of antifibrotic therapy in patients with advanced IPF.

Inhaled Particulate Matter Affects Immune Responsiveness of Human Lung Phagocytes to Mycobacteria.

Am J Physiol

The influence of smoke- or air pollution-derived cytoplasmic particulate matter (PM) can be detrimental and lead to failed lung immunity. We invest...

What Is Adaptive Servo-Ventilation (ASV)?

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page P3-P4, July 15, 2021.

Reply to Sankari and to Kawada

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 240-241, July 15, 2021.

Sleep Apnea, Pulse Rate Response, and Cardiovascular Events with Special Reference to Biomarkers

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 240-240, July 15, 2021.

Can Pulse Rate Responses Be a Metric of Cardiovascular Outcome in Patients with Obstructive Sleep Apnea?

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 239-240, July 15, 2021.

Reply to Hick and Hanfling: Social Factors and Critical Care Triage: Right Intentions, Wrong Tools

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 238-239, July 15, 2021.

Social Factors and Critical Care Triage: Right Intentions, Wrong Tools

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 237-238, July 15, 2021.

Integration of Equipoise into Eligibility Criteria in the STARRT-AKI Trial

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 234-237, July 15, 2021.

Respiratory Symptom Incidence among People Using Electronic Cigarettes, Combustible Tobacco, or Both

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 231-234, July 15, 2021.

Lipofibroblasts in Structurally Normal, Fibrotic, and Emphysematous Human Lungs

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 227-230, July 15, 2021.

Therapeutic Application of Alpha-1 Antitrypsin in COVID-19

ATS ICU

American Journal of Respiratory and Critical Care Medicine, Volume 204, Issue 2, Page 224-227, July 15, 2021.